<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma</h2>
    <div class="badge">2025-09-15T11:00:00+00:00</div>
    <ul>
      <li>2024;8:e2300702.</li>
<li>2023;41(1):75-85.</li>
<li>2022;10(12):e005755.</li>
<li>2023;41(15):2724-2735.</li>
<li>Accessed March 5, 2025.</li>
<li>2023 May 1;41(13):2454.</li>
<li>doi:10.1136/jitc-2022-005755</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma\n• 2024;8:e2300702.\n• 2023;41(1):75-85.\n• 2022;10(12):e005755.\n• 2023;41(15):2724-2735.\n• Accessed March 5, 2025.\n• 2023 May 1;41(13):2454.\n• doi:10.1136/jitc-2022-005755" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/perspective-therapeutics-progresses-dose-finding-110000210.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>